The Zhitong Finance app learned that in a media interview program on September 24 (Thursday), Sanofi (SNY.US) CEO Paul Hudson (Paul Hudson) said that it is expected that vaccines related to public health events will be prepared early next year. He pointed out that the vaccine will not enter phase III clinical trials until November or December.

Hudson also said that Sanofi is the only company that has two types of vaccines related to health incidents. One of the vaccines is being developed in collaboration with GSK.US, and early clinical trials began on September 3. Sanofi is also collaborating with Translate Bio to develop a separate vaccine with the aim of starting human trials in November.

Although Sanofi's vaccine development schedule lags slightly behind other pharmaceutical manufacturers that have begun large-scale late-stage clinical trials, Hudson expressed confidence in the company's vaccine development process. He also pointed out that even before the public health incident, the company provided about 1 billion doses of vaccine for other infectious diseases worldwide.